Home / Health / MS Drug to Boost Walking Now on NHS
MS Drug to Boost Walking Now on NHS
23 Jul
Summary
- A drug to improve walking for MS patients is now available on the NHS.
- Up to 5,000 people in England could benefit annually from the drug.
- The drug aims to improve nerve signals for better mobility and independence.
The NHS in England is now providing access to fampridine, the first drug designed to help people with multiple sclerosis improve their walking. This medication works by enhancing nerve signals, potentially enabling easier movement and greater independence for eligible patients. Up to 5,000 individuals in England may benefit annually from this treatment.
Fampridine's availability comes after previous rejections by the NHS in England due to cost-effectiveness concerns, though it was already accessible in Wales, Scotland, and Northern Ireland. Clinical trials indicated that about 40% of users experienced improvements in walking speed and endurance, which could significantly impact daily life.
Patients will undergo a one-month trial, with continued access granted only to those demonstrating a clear benefit. This initiative is expected to offer life-changing improvements for many, promoting greater freedom, confidence, and independence among those living with MS, of whom there are over 120,000 in England.
